Q3 2019 Earnings Call

Third quarter 2019 financial results conference call at this time, all participants are going to listen only mode. After the speaker presentation. There will be a question answer session asked a question. During this session you wanting to press star one or telephone if you require any further assistance. Please press star zero I would now like to have the conference.

Over to your speaker today, Peter Vozzo of Investor Relations. Please go ahead Sir.

Thank you Sonia good afternoon, everyone before we begin I would like to remind everyone that this call will contain forward looking statements, which are subject to risks and uncertainties any statements regarding future events results or expectations are forward looking statements. Please note that these forward looking statements reflect our opinions only as if the data this call we.

In addition to revise or update these forward looking statements in light of new information or future events, except as required by law information concerning factors that could cause actual results could differ materially less contained in or implied by such forward looking statements are discussed in greater detail in our Form 10-Q filed today with the FCC, especially under.

The caption risk factors I'll now turn the call over to Neil Mcfarling, Chief Executive Officer.

Thank you Peter good afternoon.

It is my first quarterly call with enormous and I'm pleased to be here with reaching Shreedhar, our chief commercial officer, Dr., Bridget Putney, our Chief Medical Officer, and Chris Apprentice, our new Chief Financial Officer, Chris assumed the role of Chief Financial Officer November after being in a senior leadership role since 2015 at Adamas I'm delighted to.

Welcome Cristobal leadership team.

It's been a exciting busy few months since the joining the joining the Domus in September what I've discovered at a domus as a company that has a healthy business with a novel therapeutic late stage pipeline and the strong cash position I'm excited to have joined the company committed to bring him go coverage to parkins disease, Parkinson's disease patients with Dyskinesias.

And on and I've been impressed with the team we have in place to drive the submission.

With his deep focus on the patients. This mission is very much aligned with my own beliefs, and I look forward to helping Adonis continue towards long term success.

As we approach your end, we remain focused on our two priorities, which are driving commercial success, pergo covering and delivering topline phase three data or an additional indication for go coverage in multiple sclerosis patients with walking impairment.

During the quarter totaled recovery prescriptions continued sequential quarter over quarter growth, which provides a continuing foundation for our future commercial initiatives.

I've spent a considerable considerable percentage of my time in the patient and physician community. What I hear very strongly is go covering works and makes a significant impact on patients daily lives and there's a tremendous opportunity to realize its potential.

As VJ will discuss the commercial team has already taken several steps to increase go covered adoption progress is being made and we're committed to learning and adjusting our strategy to build sustainable value.

While our primary focus is on on increasing demand for go covering Parkinson's disease patients with Dyskinesias given the data we expect from our inroads phase three study in the second half of December we are actively preparing to support our entry into the multiple sclerosis market.

Rajiv will review the phase three development program during his prepared remarks.

We see a significant unmet need amongst mds patients with walking impairment and are excited about the potential for go covering if approved in this highly established market.

It's important to note that adamas focuses on large treatment effects to address significant unmet needs. Therefore, we will take a disciplined and rigorous approach to assessing the inroads phase three data to ensure we can deliver a meaningful impact to patients. We anticipate that our initial commercial focus will be on those who have tried and discontinued del fan pretty.

For whom there are limited treatment options, we look forward to seem the topline data from our inroads study prior to finalizing that strategy.

Now turn the call over to VJ, who you may remember started as our chief commercial officer in June .

Thank you Neil and good afternoon, everyone. It is great to be speaking with you today.

I will begin my comments with an overview of our performance in Q3, and then provide an update on the progress we've made on the strategic priorities I highlighted on the Q2 earnings call.

Total recovery paid prescriptions that exclude product from the free trial program rose to approximately 6640 scripts, representing an increase of 8% versus Q2 of 2019 and 40% versus Q3 of last year.

While we did not have a free trial program in place to help non adopters gain clinical experience until the first quarter of this year the growth in total paid prescriptions versus last year is encouraging.

This growth continues to be driven by patients refilling the recovery.

Persistence remained strong and steady at approximately 55% to 60% at six months and 45% to 50% at 12 months again, highlighting the value that good coverage is bringing to patients.

Conversion rates from free trial to paid prescriptions also held steady between 45% to 50% registering a modest increase in the latter part of the quarter a topic I will elaborate on in a moment.

There were approximately 710, new patient starts in Q3, which included both free trial patients and new paid prescriptions for patients who did not receive the free trial.

This was generally consistent with previous quarters.

Our analysis of the quarter's performance reveals that significant growth in prescriptions from new riders was offset by a sick slight decline in use amongst some established writers. We are addressing this by optimizing our salesforce targeting to increase our share of voice in these high prescriber off.

Yes.

And improving the operational effectiveness of our fulfillment process to enhance prescriber satisfaction.

We plan to grow new patient starts by focusing on breadth. The addition of new prescribers by leveraging the four week free trial program.

And depth, increasing use among current prescribers through optimization of salesforce activity and enhancing the customer centricity of our fulfillment process.

Our interactions with thought leaders continue to reinforce the differentiated clinical profile of recovery and we remain highly optimistic about our potential for helping Parkinson's disease patients with disclosure and off.

I want to highlight that there are no other ft approved medications indicated for the treatment of disconnect in patients with Parkinson's disease and medications that are approved for the treatment of off episodes generally increase dyskinesias.

The recovery is the only product clinically proven into phase three clinical trials to significantly reduce both disclosure and off thereby increasing functional on time for parkinsons patients on leave it open therapy.

On our Q2 earnings call in August I highlighted three strategic priorities based on my initial assessment of our business I am pleased to report that we have made notable progress in each of these areas.

First we are increasing the urgency to treat but education educating healthcare practitioners to recognize the disruptive impact of dyskinesias its relationship to off and its impact on the effective treatment of Parkinson's disease.

We have recently launched a decent digital disease awareness initiatives, specifically targeting healthcare practitioners treating a high number of Parkinson's patients.

This initiative is anchored on updated web content and supplemented with new materials being delivered by our Salesforce.

The campaign focuses on the impact that disruption caused by disclosure and off has on patients activities of daily living and on how many aspects of this disruption may not be obvious to physicians during a routine patient consultation on less prioritized for proactive discussion.

Second we're improving the customer centricity of our fulfillment process to deliver one that is simple reliable and transparent towards this end. We have conducted an end to end analysis of leakage points at our fulfillment center and instituted several changes in the quarter to address them.

We are introducing a vastly simplified prescription form to reduce errors during submission.

We have also created a team of Gulf re care coordinators to serve as a dedicated single point of contact and streamline communication for clinics and patients as they initiate treatment.

This team launched on October Onest is receiving positive feedback from customers as a result of these initiatives. We have seen an early increase in the 90 day conversion rate in the last four weeks.

Our Salesforce has also been trained to deliver education to clinics, but our fulfillment process to increase transparency.

Third we are increasing awareness of our four week free trial program. We have increased branded messaging of this program through digital marketing and in the new prescription form.

And have created New reminder, resources for physician offices.

We continue to evaluate all elements of this program to expand trial, if the drug among non adopters and to serve patients better.

While these three areas what prioritized for initial focus we continue to examine every element of our strategy and execution.

I look forward to sharing additional details about our strategic and operational plans in future calls.

I will now turn it over to Rajiv to review our inroads trial.

Thanks, Vijay I'm happy to report that we remain on track to deliver topline data from our first phase three trial in M.S. walking impairment inroads by the second half of December 2019.

This double blind placebo controlled phase three study will provide efficacy and safety data of two doses of go covering 274 milligrams and 137 milligrams Q Hs or taken at bedtime.

The primary efficacy endpoint is the proportion of responders in each treatment group. After 12 weeks of double blind to treatment. A responder is defined as a patient who experienced at least a 20% increase and walking speed from baseline as measured by the time 25.

Walk test.

Secondary endpoints include the timed up and go or tug the two minute walk test and the patient reported outcome. The MSW S. 12, the power assumption and the approach to control the type whenever our standard for any pivotal trial.

It is important to recall.

This development program consists of two placebo controlled pivotal studies in roads, which I just described and a second placebo controlled study, which will be similar to inroads.

Given the greater variability of certain walking measures like the MSW West 12, compared to the time to 25 foot walk test pooling of data from both placebo controlled studies may be required.

If inroads is successful we expect to initiate the second study in 2020 if data from both studies support a sndk submission and approval we would plan to launch go recovery for this new indication and 2020 too.

We have thoughtfully defined success criteria for the inroads data first and foremost we need to ensure pristine data quality.

That is patients are not lost to follow up missing data or minimized and all database queries are answered satisfactorily prior to database lock.

In this way, we will be confident in the reliability of our conclusions from the topline data.

The other success criteria include evidence of a dose response and effect size on walking speed that is persuasive clinically and statistically and consistency across all walking efficacy measures lastly, and equally important the safety data should be on par.

With what we reported from the Phase two study.

Before I hand, the call over to Chris I will address a question. We have recently received why did we not study the effective go coverage on an EPS related fatigue.

First walking impairment in Ns isn't established market with patients in need.

Walking impairment as measured by the time to 25 foot walk test is part of the multiple sclerosis functional composite or MMS F.C. The FDA recognizes the time to 25 foot walk test as a registration efficacy endpoint since it is a direct a measure of highway patient.

Functions second.

Hey, fatigue measure is not part of the FCC and there is thus far no precedent for a fatigue related registration efficacy endpoint and Thats trials.

It is important to note.

In our view based on the literature fatigue is multifactorial, but primarily the consequence of living with M.S. related disabilities, including walking impairment.

As we reviewed at the 2019 and Congress the team increases as the day progresses. In contrast, walking impairment remains constant throughout the day third I would like to emphasize walking impairment is a type of motor impairment we have convincingly.

Demonstrated that go Cubs reduces motor impairment NPD via its effect on off and discount Nisha.

The phase two and less data suggest a positive effect on motor impairment given the efficacy signal on walking speed.

With Q Hs dosing the unique go coverage PK profile is aligned with the temporal pattern of motor impairment in both PD and Ns that is high amantadine concentrations are achieved in the morning and maintained through the day with low concentration during the night.

We look forward to the topline data from road later this year with that I will hand, the call over to Chris.

Thanks, Rajiv and good afternoon, everyone.

First I'd like to thank everyone here at a domus for supporting me and my transition to this new role I.

I certainly look forward to working with the team to accomplish our key priorities and ensuring we meet the needs of our investors.

Now, let's discuss the results for the third quarter.

Third quarter 2019 product sales were 13.9 million, a 9% increase over 12.7 million in second quarter, 2019, and a 31% increase over the same quarter last year.

For the nine for the first nine months of 2019 recovery product sales were 38.3 million compared to 20.7 million for the same period of 2018, an increase of 85%.

Regarding our overall operating results net loss for the third quarter was 27.6 million or a loss of 99 cents per share compared to a net loss of 33.2 million or a loss of about $1.22 per share in the third quarter of 2018.

R&D expenses were $6 million for the third quarter compared to $8.6 million for the prior quarter as our inroads trial completed enrollment in the second quarter.

During the third quarter of 2019, SGN, a expenses were 31.2 million compared to 25.2 million in the second quarter of 2019.

This increase is primarily due to onetime charges related to the company's CEO transition.

Despite these onetime charges, we expect both R&D and SDMA to fall within our previous annual expense guidance.

Cash and investments as of September Thirtyth 2019 were approximately 150 million.

Overall cash burn for the third quarter was down slightly from prior quarters at approximately 18 million.

Finally, our shelf is expiring later this month and as part of good financial housekeeping. We believe it is important to have an active shelf going forward.

Therefore today, we are filing a shelf registration consistent in amount with what we have previously had in place.

Let me now turn the call back over to Neil Thank you, Chris Rajiv and BJ I will now open the lines for questions operator.

Thank you as a reminder to ask the question.

Star one on your telephone.

John Your question please press the pound.

Please standby, while we compile the Kevin a roster.

Our first question comes from Marc Goodman of SVB Leerink. Your line is now open.

Hi, This is Ron arrays on the line from Mark.

I have a quick question on your comments earlier I think you mentioned the on going prescribers offset growth in new prescribers. So I was curious could you elaborate a bit on why ongoing prescribers might be lowering their use of go country or is there any other color you can give around that thanks.

Hi on this as Neil Thanks. Thanks for the question, maybe I'll start off just quickly that our new patient starts we're really stable.

Generally in line with previous quarters.

When I think about the quarter in general I think that were made tremendous progress towards listening learning in adapting executing on where we need to go I'll, maybe handed over to VJ to get into some of the specifics, but this was part of our Q3 strategy to be able to increase Brian VJ. Thank you Neil let me begin by reminding.

You on how we calculate and define new patient starts right new patient starts are the sum of patients receiving the free trial and patients who received paid new prescriptions without enrolling in the free trial.

And this comes from a combination of new riders and current writers.

So in caught in the third quarter, a major area of focus for our sales force was expanding our prescriber base.

I'm pleased to report that we expanded that bees significantly. The there was an 18% growth in new prescribers in Q3 versus Q2. So we we had a healthy growth in new prescribers starting to trial recovery.

This was offset by a slight decline in some high volume prescriber offices now why why is that.

This is a highly promotional lease sensitive space.

There are multiple players in this space right now is relatively crowded and Parkinson's disease is complex progressive and into routine visits of patients and discussions with with physicians.

The urgency to discuss disconnect and off is relatively low so what we do to our salesforce in these high prescriber offices matters.

So that is why we have taken action to.

Refine our salesforce targeting to increase our relative share of voice in these clinics.

Because we remain very optimistic and confident that we have a differentiated product profile.

And our focus on these key areas of increasing the urgency to treat and improving our fulfillment and communicating that to physicians and educating them about the free trial will get us back to growth.

Got it. Thanks, that's helpful and I just have one more question.

Regarding streamlining the process for when patients move from the Friedrich program to paid prescriptions.

Are there any metrics that you are tracking to sort of evaluate success and can you share some of my color around those.

Hey, Jeff.

We have done an end to end analysis of.

The process at our fulfillment center from when a prescription form is facts in two when a patient receives drug. So there are multiple steps in the process that we have mapped out and we have simplified each one of those processes.

In order to make it functionally easier for a physician's office to see a drug get to patient.

We're measuring this in a variety of ways the cleanest way to measure it is the 90 day.

We'll still have meant rate.

In term conversion rate in terms of free trial too.

We paid prescription why 90 days it takes that period of time for all prescriptions to work their way through the process. So as I said, we're seeing an improvement in that 90 do conversion rate.

The last few weeks of the quarter.

I might just add one thing on this you know as BJ talked about.

The fact that we've looked at the various leakage points across the fulfillment process.

It's important that we prioritize the the largest areas of leakage quickly to his point and bringing the GCC is onboard that went live last month that was a large part of the leak is we feel we could fix doesn't mean, we're over we still see opportunities to be able to add additional.

Tactics to to our fulfillment process to improve it but these were the big areas that we have analyzed and and are executing on now.

Great. Thanks.

Thank you.

Question comes from Josh Evercore ISI Your line is open.

Hey, Thanks for taking my question.

Up until.

A couple of quarters ago.

Quarter over quarter script growth was much closer to 1000.

It's recovered nicely from the second quarter third quarter, but do you think it is.

Plausible to get the script growth back into the thousand.

Quarter range, what might it take.

How long.

VJ.

Let me begin with noting what you just said there we have made notable progress in terms of our top focus areas in this quarter.

The way that we approached it and we set up to three key focus areas of urgency increasing urgency to treat improving fulfillment and increasing awareness and use of our free trial program was because we identified these as key barriers to increasing our demand and therefore, we quickly instituted changes too.

Address these barriers by focusing on the largest levers first.

So these changes as you saw in my prepared remarks have just been implemented there are more coming in phases.

The early signs of what we have implemented.

And the early reception to these changes have been largely positive.

As Neil mentioned in his remarks, we are continuing to learn and adapt.

Execute as we continue to execute as fast as we can and we remain optimistic about our prospects overtime.

So that's why our focus remains increasing breadth and depth and I think the changes were starting to make.

We'll have impact over time.

Thank you.

Your next question comes from David Amsellem of Piper Jaffray. Your line is open.

Okay.

Thanks, just a couple sorry, if I missed this but what you said is the conversion rate now and you know with the improvements where do you expect it to be steady state.

Realistically.

So that's number one number two is.

In terms of sampling.

How long do you think you're going to be sampling of units this going to be just a permanent feature.

Your commercial execution strategy.

And then lastly, what's the average co pay right now.

For patients it was just remind us on that thanks.

Great Hi, David says, Neil maybe I'll start with the conversion, it's held steady at 45% to 50% and again lot of what VJ has talked about on executing our fulfillment process to simplify it to make it more reliable make a transparent educate our field organization.

Coming through I was in the field last week with one of our top prescribers that are an MD essar and and as I was leaving the office. The medical assistance said, we really appreciate having a single point of contact.

That was after it only had been instituted for less than three weeks. So I think that there is some some real benefits to us having the simplified format and the rest of the questions I'll hand over to VJ see if you could do a better job.

We.

To add onto what Neil just talked about the 90 day fulfillment rate, we have been tracking quite carefully to the previous question as well and we see that tracking up steadily and we're very encouraged by the early signs that we see.

In terms of your question about.

The physical samples.

I would say that this is not intended to to be and an unending program on the free trial aspect.

We remind you.

That are prescriber base.

Still has a lot of room for growth. So our full unlocking of the potential of go very depends on both.

Yep among current writers, but also breadth to get more new riders into the system trial and good coverage that is walk the free trial program is intended to do and we're having good progress in increasing breadth of utilization, which we're very pleased to see and we'll keep the program in place as long as we see an opportunity for us to for.

The increase breadth you asked a question about.

The co pays that we're seeing come through I'm pleased to report that from our latest data.

Off the patients that received go covering 75% of the time, they're out of pocket expenses are $25 or less so we're very encouraged about that and I'm pleased to see that and we continue of course to remain committed to making the recovery as broadly available to patients as possible.

Thank you and our next question comes from Ken Kesey Cowen and company. Your line is now open.

Hey, guys that may have an overly simplistic question, but with the did you control the employees or were they your employees at the fulfillment center previously in our the your employees now I'm just trying to understand.

What might have been happening when they were not getting a form that seem to correct like what was their motivation to get it fixed it. It seems like something was going wrong, there and I want to make sure that your country and complete control of that process that you talked about us more simplistic form is that from a clinician standpoint, because it seems like it perform head to head in it.

Issue and it came to one of your employees, everyone would work like heck to try to.

Clarify it and get it.

So just wanted to understand are you now in complete control of the fulfillment process and then also maybe osmolarity and their impact in their sampling is that part of the problem or is that really not an issue at all thank you.

Sure. So let me address the first question in terms of the fulfillment process. Our end to end analysis of the process revealed that every stage of the process had a different point of contact for a physician's office and or a patient right. They would reaching different people different people what reaching.

Now to them the Gulf we care coordinator team is a single dedicated point of contact with the physician as well as to the patient. These our employees of alliance Rx. However, they are fully dedicated to the recovery business and we are very tightly coordinating with them.

They essentially serve as the quarterbacks within the alliance arc system to streamline the communication among the players who help with the various steps of the process so that to the customer the communication is highly streamlined.

And there's a there's a resolution of issues that might pop up much quicker than we might have seen before.

To your question of competition.

We do see presence of physical samples and activity by all small X, but let me begin with the fact that go from our prepared remarks, what you heard was what physicians stellus.

They continue to seek recovery as a highly differentiated product.

We have a very differentiated profile in that we're the only ones with that if the indication for the treatment of disconnect.

The only once with a proven clinical benefit in both Dyskinesias and off in an increasing on time and we're the only once with Q Hs bedtime dosing.

So physicians continue to see us as highly differentiated and we don't see an impact right now have a competitive product in this space.

Ken maybe I'll add just one thing to that when you asked a question around whether or not there ours.

They were or domus employees or not.

There are domus trained.

On the product they're aligned in terms of what our incentives are on making sure that patients get product and simplifying the process of fulfillment. So I think it's a tight and there's a tight matrix to be able to assure that these guys are delivering what we would want to deliver so I want to make it clear that.

We feel like there is a a tight consistency between what they are delivering in how we were delivered ourselves so.

Thank you.

Thank you and our next question comes from.

William Blair. Your line is now open.

Thanks for taking my question congratulations.

The first call.

I guess quickly around the new prescribers.

As well as losing some of the park prescribers that previously been pursuing but globally.

I think that's going to lead to Trx is still growing up around the same we've seen well past few quarters and falling on a previous question.

Isn't maybe you prescription garland in not growing sequentially. The thousand however, they are going and 100, and then just higher quality therefore more sticky.

Thank you maybe can you smell mall.

More details around that.

Hey, Tim I'm going to take a stab at the first one which which we've talked about the fact that as part of growing this.

Prescriber base away from just the depth on where we were were really put a consistent effort in Q3 to being able to broaden that that brought the prescribers and 18% increase has nothing to shake a stick at I think the team did an outstanding job in doing that.

And this is actually I think the first time, where we've seen this type of increase in BRAF. The opportunity. When somebody has that means we're able to get that urgency to treat that means we're able to actually get that that fulfillment going and thats pre trial program is working so it's kind of validating our our current tactics.

But when we now have that that broad base. We can go deep now so it allows for the Trx and Nbrx.

Ticket to improve so maybe I'll switch to BJ can get into some additional details.

Increasing demand is an utmost urgency for us. So so let there'll be no misconception on that front and we are therefore focused on increasing as Neal said, both the breadth of prescriber base and the depth.

And we are appropriately allocating our sales force targeting to ensure that both can happen.

We saw great success with the breadth aspect in Q3, we have some work to do on the depth aspect and we are focused on that right now and we firmly believe that our progress in the three key focus areas will get us there.

Okay can you, maybe tidelands back a bit too as.

Well.

Should we just.

It took stuff.

That's now yes units.

Deepening into these new prescribers.

Or you know because it sounds like there might be some optimization maybe just.

Deeper into the new prescribers will so along the same level spend.

So I'll take a quick stem, we'll see if we can't get Chris engaged in this call.

VJ has done a great job on looking at the assessment of what we need to be able to accelerate growth in.

PD.

We feel at this point, we're adequately sized sees moving again his is.

Targeting and refining is targeting as he is going so I think we're in pretty good shape, but I'll hand, it over Chris on the M&A side. So you can actually have a horse here today too.

Thanks Neil.

Obviously PD is our key priority that were completely focused on we've asked VJ and the team to really continue to look at the priorities in the tactics that he wants to focus on and we're reallocating reallocating the resources, we need to to continue to focus on things that truly drive the business.

But yet.

Make this our key priority, but yet not overspend, so VJ and team have done a really good job just continuing to look at what's important to drive the business.

And right now where we are focused on is optimizing the marketing mix in terms of salesforce targeting versus digital marketing to provide the necessary share of voice we need.

Okay, and maybe if I could sneak in one pipeline question. Thank you for all the commentary around enroll in kind of.

What you will view as a success.

However, the first point in terms of pristine data. It seems like you probably have a good idea about trial conduct.

As of now.

Early November curious maybe speak to the trial conduct.

You know how confident you are that there will be.

Christine.

Come December .

Thank you will get you in here too so thanks for the question.

We are very confident.

In the trial conduct.

And as Neil mentioned, I say that based on our experiences with the PD program.

So we will achieve high quality data, which a step one and any phase three data readout, we did NPD well due to an Ns.

Great to hear festival.

Thanks, Tim.

Thank you and your next question comes from rents on marriage, you have H.C. Wainwright. Your line is open.

Hi.

And Ryan microphone is Amit please UN mute.

And again I question comes from ramps of energy of H.C. Wainwright.

Yes. Thank you for taking my question can you hear me.

We've got to Ron.

Yes. Thank you. So I just wanted to get some additional clarity regarding where the new patients are coming from and what the profile of the prescribers are that are bringing on board those new patients. If you could elaborate on that please what's the profile in other words of the prescriber base.

From which the new patients who are coming onto the product it.

VJ.

We see we think for the question from the mix of prescribers that we see.

Our some new high volume prescribers that have not prescribed previously we're just trialing the drug for the first time as wireless as well as some prescribers, who treat lower volumes of.

Parkinson's disease patient, so we see a mix in terms of where we get the breadth from.

Okay, and then with respect to the retention profile.

If we think about what's the original expectations were regarding go coverage long term retention dynamics at the time that the product was first introduced and we look at the profile that has emerged now is this overall in keeping with what you originally anticipated or is that a new picture.

That has emerged in particular I'm talking about those figures that you previously provided regarding the roughly 60% retention rate at six months and 45% to 50% at 12 months.

Yes. So so to address that question. We are very pleased both from a persistency perspective, and a compliance perspective in terms of how patients stay on the drug. So so in terms of both those key metrics.

We continue to see a continued highlighting the value that patients see in the drop they stay on the drugs. So for a condition of this nature, we're very pleased with what we've seen.

Okay and then the last question is pertaining to the inroads indication.

Given that there would be evidence supporting the use of recovery as.

Ameliorate or of walking impairments does this have any implications for potential explorations in indications beyond specifically and that's in other words are there other related conditions in which on a positive impact on walking impairment would potentially be beneficial and point too.

The possibility of utility and those contracts.

Dr. Petty appreciate the question.

As I said in my prepared remarks about go covered today and motor impairment.

We have NPD.

We hope to demonstrate that and the first pivotal NMS.

If two disease area show in effect and motor impairment.

Of course will make us think as a company of is there an additional.

Population, where we should study go coverage and I say that because back in his opening comments. This about it isn't about maximizing patient benefit with where to go cover we can have a large effect size. So if we see it then yes is the answer.

Seriously explore whereas where else in a distinct patient population.

Go covering can provide that patient benefit.

Great and just one clarification Torrey point you were talking previously about the possibility of pooling of data from the inroads study and putative confirmatory trial, but can you just clarify whether what you meant was just broadly speaking pooling of data towards.

Steve Statistical robustness or if what is implied was pooling with respect to certain pre specified subgroup analyses.

What I meant and I appreciate the the request for clarity pooling of data with respect to certain secondary efficacy measures and in particular that patient reported outcome, the and SWS 12.

Pete Rose in general theme and SWS 12, as an example, being appealed ROE have inherently high value ability.

And the most straightforward way to deal with that is to pull data to just be more per site in the treatment effect point estimate.

Great. Thank you very much.

Yeah, and ladies gentlemen, this does question answer session.

I will call back over to nail Macfarlane for any closing remarks.

Thank you Sanya I want to thank everybody for the warm welcome that I've received since joining the Domus. We remain focused on our two top priorities driving growth recovery in Parkinson's disease patients with this can Asia in off along with completing our inroads phase three study in the second half of December we look forward to continue in the dialogue and providing updates at up kind of.

Upcoming investor conferences, and quarterly call have a good afternoon.

Hello, Ladies and gentlemen. This concludes today's conference call. Thank you for participating you may now disconnect.